The company also has an eye on emerging categories like peptides, banking on a regulatory push to expand peptide access
Looking forward, the GLP-1 drugs we study (semaglutide, tirzepatide, and emerging oral formulations like orforglipron) are likely only the beginning of a new wave of chronic therapies for conditions like obesity, heart failure, and even kidney disease
there are effective strategies to help manage these challenges: Start Slowly: Begin with the lowest dose and gradually increase it, allowing your body the time it needs to adjust
This dual action leads to greater appetite control, improved insulin sensitivity, and potentially more significant weight loss results compared to GLP 1s alone
These injectable medications may be beneficial for individuals who have struggled to achieve meaningful weight loss through traditional methods alone